Hepatocellular Carcinoma (HCC) Surgery | Liver Resection and Multidisciplinary Care

Liver tumors require careful integration of tumor biology, hepatic anatomy, and underlying liver function to ensure safe treatment while preserving adequate hepatic reserve. This section reflects a focused hepatopancreatobiliary (HPB) surgical oncology practice dedicated to complex liver diseases including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, colorectal liver metastases, and selected benign hepatic tumors.

Hepatocellular Carcinoma Surgery in the Context of Tumor Biology and Liver Function

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and most often develops in the setting of chronic liver disease or cirrhosis. Management of HCC differs from many other solid tumors because treatment decisions must balance oncologic tumor control with preservation of adequate liver function.

Unlike metastatic liver tumors, which arise from cancers elsewhere in the body, hepatocellular carcinoma develops directly from hepatocytes, the primary functional cells of the liver. Surgical decision-making therefore requires simultaneous evaluation of:

  • Tumor burden and distribution

  • Vascular anatomy

  • Underlying liver function

  • Future liver remnant volume

  • Overall tumor biology

As a fellowship-trained robotic surgical oncologist and hepatopancreatobiliary (HPB) surgeon serving the San Francisco Bay Area, Dr. Geoffrey W. Krampitz specializes in the surgical management of liver tumors, including liver resection for carefully selected patients with hepatocellular carcinoma.

Care is delivered within a coordinated multidisciplinary framework integrating surgical oncology, hepatology, medical oncology, interventional radiology, transplant specialists, and advanced imaging.

The biology of hepatobiliary malignancies — including mechanisms of tumor progression, vascular invasion, and treatment response — has been an ongoing academic interest throughout Dr. Krampitz’s surgical and research training. This translational perspective informs surgical decision-making and multidisciplinary treatment sequencing.

Risk Factors and Disease Development

Hepatocellular carcinoma most commonly arises in patients with chronic liver injury or cirrhosis. Major risk factors include:

  • Cirrhosis from any cause

  • Chronic hepatitis B infection

  • Chronic hepatitis C infection

  • Nonalcoholic fatty liver disease (NAFLD) or steatohepatitis

  • Alcohol-related liver disease

  • Certain metabolic or genetic liver disorders

Because patients with cirrhosis are at elevated risk, routine surveillance imaging is often recommended to detect tumors at an earlier, potentially curable stage.

Symptoms of Hepatocellular Carcinoma

Early-stage HCC frequently causes no symptoms and is often detected through surveillance imaging in patients with cirrhosis.

When symptoms occur, they may include:

  • Right upper abdominal discomfort

  • Unintentional weight loss

  • Fatigue

  • Abdominal swelling (ascites)

  • Jaundice

However, many patients remain asymptomatic until tumors grow larger or liver function declines.

Diagnosis and Staging

Accurate staging requires assessment of both tumor characteristics and underlying liver function.

Imaging

Diagnosis typically relies on high-quality cross-sectional imaging, including:

  • Multiphasic CT scan or MRI of the liver

  • CT scan of the chest

  • Additional imaging when clinically indicated

In patients with cirrhosis, characteristic arterial phase enhancement with venous washout on imaging can establish the diagnosis without biopsy.

Laboratory Evaluation

Laboratory testing may include:

  • Alpha-fetoprotein (AFP)

  • Liver function tests

  • Coagulation profile

Evaluation of hepatic reserve is essential and commonly includes Child-Pugh classification and MELD score assessment.

Staging and Treatment Framework

Treatment planning integrates tumor stage with liver function.

Several staging systems exist, but the Barcelona Clinic Liver Cancer (BCLC) staging system is widely used to guide management. This framework incorporates:

  • Tumor burden and vascular invasion

  • Presence of extrahepatic spread

  • Liver function and performance status

Because HCC frequently develops in cirrhotic livers, treatment strategies must be individualized based on both oncologic and physiologic considerations.

Emerging Molecular Insights in Hepatocellular Carcinoma

Advances in genomic and molecular profiling are increasingly improving understanding of hepatocellular carcinoma biology. While surgical decision-making remains primarily guided by tumor stage and liver function, emerging molecular insights are beginning to refine risk stratification and systemic therapy selection.

HCC demonstrates significant molecular heterogeneity, with commonly described alterations involving pathways related to:

  • TERT promoter activation

  • Wnt/β-catenin signaling (CTNNB1 mutations)

  • TP53 tumor suppressor alterations

  • Chromatin remodeling genes

  • Angiogenesis and growth factor signaling

These molecular changes contribute to differences in tumor behavior, including growth rate, vascular invasion, and response to systemic therapies.

Recent research has also explored molecular predictors of response to immunotherapy and targeted agents, as well as biomarkers associated with recurrence risk following resection or transplantation.

Although molecular classification does not yet replace established staging systems such as the Barcelona Clinic Liver Cancer (BCLC) framework, ongoing translational research is expanding the role of molecular characterization in hepatocellular carcinoma and may increasingly influence treatment sequencing in the future.

For additional discussion of biomarker-driven strategy in gastrointestinal cancers, see Molecular Oncology & Surgical Strategy.

Treatment Strategy for Hepatocellular Carcinoma

Management of HCC may involve several treatment modalities depending on stage and liver reserve, including:

  • Surgical resection

  • Liver transplantation

  • Thermal and non-thermal ablation

  • Transarterial embolization therapies

  • Systemic therapy

Treatment sequencing is determined through multidisciplinary evaluation integrating hepatology, oncology, transplant surgery, and interventional radiology.

Liver Resection for Hepatocellular Carcinoma

Liver resection (partial hepatectomy) involves removal of the tumor-bearing portion of the liver while preserving sufficient healthy liver tissue.

Surgery may be recommended for carefully selected patients with:

  • Solitary tumors

  • Limited multifocal disease

  • Preserved liver function

  • Absence of major vascular invasion

The liver’s regenerative capacity allows safe removal of segments or lobes when an adequate future liver remnant can be preserved.

The goal of surgery is complete tumor removal with negative margins while maintaining adequate functional liver reserve.

Liver Transplantation in Selected Patients

In patients with early-stage HCC and cirrhosis, liver transplantation may be considered.

Transplantation removes both the tumor and the underlying cirrhotic liver, reducing recurrence risk associated with chronic liver disease.

Eligibility depends on tumor size, number of lesions, and absence of extrahepatic spread. Evaluation is performed in collaboration with transplant specialists.

Liver-Directed Therapies

For patients who are not candidates for immediate surgery or transplantation, liver-directed therapies may be used to control tumor growth or downstage disease.

Ablation

Thermal ablation techniques such as:

  • Radiofrequency ablation (RFA)

  • Microwave ablation

may be effective for small tumors, typically less than 3 cm.

Embolization Therapies

Embolization treatments deliver therapy directly to the tumor’s arterial blood supply and may include:

  • Transarterial chemoembolization (TACE)

  • Radioembolization (Y-90)

  • Bland embolization

These therapies may be used for tumor control, bridging to transplantation, or downstaging prior to surgical resection.

Emerging Non-Thermal Ablation Technologies

In addition to established thermal ablation techniques, histotripsy is an emerging non-invasive technology under active clinical investigation for selected liver tumors. Histotripsy uses focused ultrasound to generate microscopic cavitation bubbles within tissue, mechanically disrupting tumor cells without the use of heat or needles.

Because this technique is non-thermal and extracorporeal, it may offer theoretical advantages in treating tumors located near critical vascular or biliary structures where conventional thermal ablation carries risk of collateral injury.

Histotripsy remains an evolving technology, and its role in hepatocellular carcinoma and other hepatopancreatobiliary tumors continues to be studied in clinical trials.

Robotic and Minimally Invasive Liver Surgery

When anatomically appropriate, selected liver resections for HCC may be performed using advanced robotic-assisted techniques.

Robotic platforms provide:

  • Enhanced three-dimensional visualization

  • Improved instrument articulation

  • Greater precision during parenchymal transection and vascular control

Technology does not supersede surgical judgment. Operative approach is determined by tumor location, liver function, vascular anatomy, and overall patient safety.

Learn more about advanced techniques in Robotic Surgery.

Programmatic Expertise in Liver Surgery

Hepatic surgery requires a detailed understanding of segmental liver anatomy, vascular inflow and outflow, and preservation of adequate functional liver remnant.

Why experience matters in liver surgery:
Outcomes following hepatectomy are closely associated with surgeon expertise, multidisciplinary coordination, and careful patient selection — factors that influence complication management, oncologic margins, and long-term survival.

Care is delivered within an experienced HPB-focused program committed to oncologic rigor, biologic interpretation, and safe hepatic resection.

Multidisciplinary Hepatocellular Carcinoma Care

Optimal management of HCC requires coordinated collaboration among:

  • Surgical oncology

  • Hepatology

  • Medical oncology

  • Interventional radiology

  • Radiation oncology

  • Transplant specialists

  • Radiology and pathology

Treatment sequencing aligns surgery, liver-directed therapies, systemic therapy, and transplant evaluation with tumor biology and liver function.

Consultation and Referral

For Patients:
Individuals seeking evaluation for hepatocellular carcinoma — including new diagnoses or second opinions — may Request a Consultation to discuss individualized treatment strategy.

For Referring Physicians:
Physicians wishing to refer a patient or discuss complex liver tumors may visit For Physicians for direct referral pathways and coordinated case review.